Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

Journal of the Neurological Sciences

Volumn 168, Issue 2, 1999, Pages 131-136

  Antonelli, Guido ^a,b   Simeoni, Eleonora ^c   Bagnato, Francesca ^c   Pozzilli, Carlo ^c   Turriziani, Ombretta ^c   Tesoro, Ramon ^c   Di Marco, Paola ^c   Gasperini, Claudio ^d   Fieschi, Cesare ^c   Dianzani, Ferdinando ^c,e  

^a UNIVERSITY OF PISA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Antibody to interferon beta; Interferon; Interferon beta; Interferon beta 1a; Interferon beta 1b; Multiple sclerosis; Relapsing remitting multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENCE RISK; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; ANTIBODY SPECIFICITY; BINDING, COMPETITIVE; CROSS-OVER STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS; RECURRENCE; REMISSION, SPONTANEOUS; RETROSPECTIVE STUDIES;

EID: 0032858799     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00185-9     Document Type: Article

References (28)

1. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of a randomized controlled trial. Neurology. 45:1995;1277-1285.
2. Jacobs L.D., Cookfars D.L., Rudick R.A., et al. Intramuscolar interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet. 7:1998;1498-504.
4. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 7:1998;1491-1497.
5. Antonelli G. In vivo development of neutralizing antibodies to interferons: an update to 1996. J. Inteferon Cytokine Res. 17:1997;S39-S46.
6. Neutralizing antibodies using treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology. 47:1996;889-894.
7. Rudick R.A., Simonian N.A., Alam J.A. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 50:1998;1266-1272.
8. Antonelli G., Bagnato F., Pozzilli C. Development of neutralizing antibodies in patients with multiple sclerosis treated with IFN-β1a. J. Inteferon Cytokine Res. 18:1998;345-350.
9. Kivisakk P., Alm G.V., Tian W.Z. Neutralizing and binding anti-interferon-β-1b (IFNβ-1b) antibodies during IFNβ-1b treatment in multiple sclerosis. Multiple Sclerosis. 3:1997;184-190.
10. Petkau J., White R. Neutralizing antibodies and the efficacy of interferon beta-1a in relapsing remitting multiple sclerosis. Multiple Sclerosis. 1:1997;402.
11. Abdul-Ahad A.K., Galazka A.R., Revel M. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon β-b1a from mammalian cells. Cytokines Cell. Mol. Ther. 3:1997;27-32.
12. Larocca A.P., Steven C.L., Stephen G.M. Evaluation of neutralizing antibodies in patients treated with recombinant Interferon-beta. J. Interferon Res. 9:1989;S51-S60.
13. Kagawa Y., Takasaki S., Ustumi J. Comparative study of the asparagine-linked sugar chains of natural human interferon-β1 and recombinant human interferon-β1 produced by three different mammalian cells. J. Biol. Chem. 263:1988;17508-15.
14. Derynck R., Remaut E., Saman E. Expression of the human fibroblast interferon gene in Escherichia coli. Nature. 287:1980;193-197.
15. Mark D.F., Lu S.D., Creasey A.A. Site-specific mutagenesis of human fibroblast interferon gene. Proc. Natl. Acad. Sci. USA. 81:1984;5662-5666.
16. Khan O.A., Dhib-Jalbut S.S. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive. Neurology. 51:1998;1698-1702.
17. Antonelli G., Currenti M., Turriziani O. Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparation. J. Infect. Dis. 163:1991;882-885.
18. Gribben J.G., Devereux S., Thomas N.S.B., et al. Development of antibodies to unprotected glycosilation sites on recombinant human GM-CSF. Lancet. 335:1990;434-437.
19. Poser C.M., Paty D.W., Scheineberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
20. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol. 19:1986;558-563.
21. Grossberg S.E., Kawade Y. The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotherapy. 10:1997;93-98.
22. Arnason B.G., Dianzani F. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy. J. Interferon Cytokine Res. 18:1998;639-644. Summary of an International Workshop on Anti-Interferon Antibodies.
23. Runkel L., Werner M., Blake R. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharmaceutical Res. 15:1998;641-649.
24. Roffi L., Colloredo Mels G., Antonelli G. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology. 21:1995;645-649.
25. Finter N.B. Why are there so many subtypes of alpha-interferons? J. Interferon Res. 1991;185-194. Special issue.
26. Viscomi G.C., Grimaldi M., Palazzini E. Human leukocytes IFN alpha: structure, pharmacology and therapeutic application. Medical Res. Reviews. 15:(5):1995;445-478.
27. Brand C.M., Leadbeater L., Bellati G. Characterization of anti-interferon-alpha antibodies appearing during recombinant-interferon-alpha-2 treatment. Clin. Exp. Immunol. 89:1992;330-335.
28. Ross C., Svenson M., Koch-Henriksen N. A randomized comparative study of antibody development to IFNβ-1a and IFNβ-1b in patients with multiple sclerosis. Europ. Cytokine Net. 9:1998;502.